Neurological dysfunctions associated with altered BACE 1‐dependent Neuregulin‐1 signaling
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Inhibition of BACE 1 is being pursued as a therapeutic target to treat patients suffering from Alzheimer's disease because BACE 1 is the sole β‐secretase that generates β‐amyloid peptide. Knowledge regarding other cellular functions of BACE 1 is therefore critical for the safe use of BACE 1 inhibitors in human patients. Neuregulin‐1 (Nrg1) is a BACE 1 substrate and BACE 1 cleavage of Nrg1 is critical for signaling functions in myelination, remyelination, synaptic plasticity, normal psychiatric behaviors, and maintenance of muscle spindles. This review summarizes the most recent discoveries associated with BACE 1‐dependent Nrg1 signaling in these areas. This body of knowledge will help to provide guidance for preventing unwanted Nrg1‐based side effects following BACE 1 inhibition in humans. image To initiate its signaling cascade, membrane anchored Neuregulin (Nrg), mainly type I and III β1 Nrg1 isoforms and Nrg3, requires ectodomain shedding. BACE 1 is one of such indispensable sheddases to release the functional Nrg signaling fragment. The dependence of Nrg on the cleavage by BACE 1 is best manifested by disrupting the critical role of Nrg in the control of axonal myelination, schizophrenic behaviors as well as the formation and maintenance of muscle spindles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Insel, T. R. (2010) · Nature · doi:10.1038/nature09552 · Cited by 1,783
De novo mutations in schizophrenia implicate synaptic networks
Fromer, M., Pocklington, A. J., Kavanagh, D. H., Williams, H. J., Dwyer, S., Gormley, P., Georgieva, L., Rees, E., Palta, P., Ruderfer, D. M., et al. (2014) · Nature · doi:10.1038/nature12929 · Cited by 1,617
Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526 · cited 1×
“For example, Ab42, but not Ab40, has been found to induce tau pathogenesis (Gotz et al. 2001; Rank et al. 2002; Blurton-Jones and LaFerla 2006; Liraz et al. 2013; Hu et al. 2014), which is another major pathological feature in AD brains.”
BackgroundBorchelt, D. R., Thinakaran, G., Eckman, C. B., Lee, M. K., Davenport, F., Ratovitsky, T., Prada, C.-M., Kim, G., Seekins, S., Yager, D., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80230-5 · Cited by 1,478
Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity
Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M., Brashler, J. R., Stratman, N. C., Mathews, W. R., Buhl, A. E., et al. (1999) · Nature · doi:10.1038/990107 · Cited by 1,438
Self-citationA polygenic burden of rare disruptive mutations in schizophrenia
Purcell, S. M., Moran, J. L., Fromer, M., Ruderfer, D., Solovieff, N., Roussos, P., O’Dushlaine, C., Chambert, K., Bergen, S. E., Kähler, A., et al. (2014) · Nature · doi:10.1038/nature12975 · Cited by 1,385
Citron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-wood, K., Lee, M., Seubert, P., Davis, A., et al. (1997) · Nature Medicine · doi:10.1038/nm0197-67 · Cited by 1,271 · cited 5×
“Since BACE1 is critical for Ab generation, inhibition of BACE1 should reduce levels of Ab, particularly the more toxic Ab42, which could benefit AD patients.”
BackgroundInfluentialGong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., & Klein, W. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834302100 · Cited by 1,061 · cited 1×
“In brains of patients with Alzheimer’s disease (AD), abnormally accumulated Ab tends to oligomerize, aggregate and induce synaptic dysfunction and memory loss (Walsh et al. 2002; Gong et al. 2003; Haass and Selkoe 2007; Wang et al. 2013; Price et al. 2014; Tu et al. 2014).”
BackgroundNeuregulin 1 in neural development, synaptic plasticity and schizophrenia
Mei, L., & Xiong, W.-C. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2392 · Cited by 1,030
Luo, Y., Bolon, B., Kahn, S., Bennett, B. D., Babu-Khan, S., Denis, P., Fan, W., Kha, H., Zhang, J., Gong, Y., et al. (2001) · Nature Neuroscience · doi:10.1038/85059 · Cited by 1,001
Cited by
Kondo, T., Imamura, K., Funayama, M., Tsukita, K., Miyake, M., Ohta, A., Woltjen, K., Nakagawa, M., Asada, T., Arai, T., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.109 · Cited by 221
Wessels, A. M., Tariot, P. N., Zimmer, J. A., Selzler, K. J., Bragg, S. M., Andersen, S. W., Landry, J., Krull, J. H., Downing, A. M., Willis, B. A., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.3988 · Cited by 209
Investigational BACE inhibitors for the treatment of Alzheimer’s disease
Imbimbo, B. P., & Watling, M. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1683160 · Cited by 132
BACE1 regulates the proliferation and cellular functions of Schwann cells
Hu, X., Hou, H., Bastian, C., He, W., Qiu, S., Ge, Y., Yin, X., Kidd, G. J., Brunet, S., Trapp, B. D., et al. (2017) · Glia · doi:10.1002/glia.23122 · Cited by 27
Self-citationUsing machine intelligence to uncover Alzheimer’s disease progression heterogeneity
Qorri, B., Tsay, M., Agrawal, A., Au, R., & Gracie, J. (2020) · Exploration of Medicine · doi:10.37349/emed.2020.00026 · Cited by 13
Metadata
- Authors
- Hu, X., Fan, Q., Hou, H., & Yan, R.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2015-11-13
- Volume
- 136
- Issue
- 2
- Pages
- 234-249
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2157577485
- Cited by
- 52
- References
- 30
- FWCI
- 4.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.